Guggenheim Capital’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $917K | Sell |
51,046
-7,483
| -13% | -$142K | 0.01% | 1060 |
|
|
2026
Q1 | $1.27M | Buy |
58,529
+6,587
| +13% | +$127K | 0.01% | 891 |
|
|
2025
Q4 | $1.12M | Sell |
51,942
-4,847
| -9% | -$102K | 0.01% | 896 |
|
|
2025
Q3 | $1.09M | Buy |
56,789
+10,999
| +24% | +$196K | 0.01% | 898 |
|
|
2025
Q2 | $783K | Buy |
45,790
+11,497
| +34% | +$490K | 0.01% | 976 |
|
|
2025
Q1 | $2.19M | Buy |
34,293
+1,882
| +6% | +$198K | 0.02% | 620 |
|
|
2024
Q4 | $3.94M | Sell |
32,411
-236
| -0.7% | -$28.9K | 0.03% | 481 |
|
|
2024
Q3 | $4.08M | Buy |
32,647
+1,773
| +6% | +$245K | 0.03% | 596 |
|
|
2024
Q2 | $4.88M | Buy |
30,874
+4,539
| +17% | +$583K | 0.03% | 527 |
|
|
2024
Q1 | $3.41M | Buy |
26,335
+2,526
| +11% | +$309K | 0.02% | 691 |
|
|
2023
Q4 | $2.3M | Buy |
23,809
+289
| +1% | +$27.7K | 0.02% | 787 |
|
|
2023
Q3 | $2.85M | Sell |
23,520
-412
| -2% | -$46.6K | 0.02% | 686 |
|
|
2023
Q2 | $2.74M | Buy |
23,932
+112
| +0.5% | +$14.4K | 0.02% | 731 |
|
|
2023
Q1 | $3.28M | Sell |
23,820
-6,702
| -22% | -$869K | 0.03% | 667 |
|
|
2022
Q4 | $3.96M | Sell |
30,522
-1,477
| -5% | -$171K | 0.03% | 613 |
|
|
2022
Q3 | $3.54M | Sell |
31,999
-9,513
| -23% | -$959K | 0.03% | 625 |
|
|
2022
Q2 | $3.11M | Buy |
41,512
+22
| +0.1% | +$1.62K | 0.02% | 729 |
|
|
2022
Q1 | $3.24M | Sell |
41,490
-388
| -0.9% | -$29.7K | 0.02% | 823 |
|
|
2021
Q4 | $3.77M | Buy |
41,878
+3,855
| +10% | +$330K | 0.02% | 794 |
|
|
2021
Q3 | $3.52M | Sell |
38,023
-733
| -2% | -$56.5K | 0.02% | 802 |
|
|
2021
Q2 | $3.01M | Sell |
38,756
-2,890
| -7% | -$219K | 0.02% | 885 |
|
|
2021
Q1 | $3.1M | Buy |
41,646
+11,104
| +36% | +$1.02M | 0.02% | 817 |
|
|
2020
Q4 | $5.21M | Sell |
30,542
-3,359
| -10% | -$498K | 0.03% | 556 |
|
|
2020
Q3 | $4.76M | Sell |
33,901
-5,198
| -13% | -$790K | 0.03% | 549 |
|
|
2020
Q2 | $6.27M | Buy |
39,099
+5,020
| +15% | +$683K | 0.05% | 434 |
|
|
2020
Q1 | $3.33M | Sell |
34,079
-7,014
| -17% | -$802K | 0.03% | 607 |
|
|
2019
Q4 | $5.3M | Sell |
41,093
-1,929
| -4% | -$195K | 0.04% | 599 |
|
|
2019
Q3 | $3.24M | Buy |
43,022
+2,857
| +7% | +$337K | 0.03% | 809 |
|
|
2019
Q2 | $6.1M | Sell |
40,165
-6,400
| -14% | -$778K | 0.05% | 494 |
|
|
2019
Q1 | $5.55M | Sell |
46,565
-1,665
| -3% | -$214K | 0.05% | 559 |
|
|
2018
Q4 | $5.26M | Buy |
48,230
+5,838
| +14% | +$730K | 0.04% | 539 |
|
|
2018
Q3 | $6.85M | Sell |
42,392
-7,275
| -15% | -$995K | 0.04% | 530 |
|
|
2018
Q2 | $6.56M | Sell |
49,667
-7,329
| -13% | -$691K | 0.04% | 543 |
|
|
2018
Q1 | $4.22M | Sell |
56,996
-8,351
| -13% | -$557K | 0.01% | 1118 |
|
|
2017
Q4 | $3.63M | Sell |
65,347
-18,370
| -22% | -$973K | 0.01% | 1224 |
|
|
2017
Q3 | $3.8M | Buy |
83,717
+167
| +0.2% | +$6.67K | 0.01% | 1221 |
|
|
2017
Q2 | $2.82M | Sell |
83,550
-3,923
| -4% | -$128K | 0.01% | 1372 |
|
|
2017
Q1 | $2.59M | Buy |
87,473
+1,704
| +2% | +$52.7K | 0.01% | 1467 |
|
|
2016
Q4 | $2.35M | Sell |
85,769
-7,641
| -8% | -$307K | 0.01% | 1550 |
|
|
2016
Q3 | $5.74M | Sell |
93,410
-30,459
| -25% | -$921K | 0.02% | 945 |
|
|
2016
Q2 | $2.36M | Buy |
+123,869
| New | +$2.29M | 0.01% | 1455 |
|
|
2016
Q1 | – | Sell |
-126,065
| Closed | -$4.86M | – | 2990 |
|
|
2015
Q4 | $4.86M | Buy |
126,065
+59,721
| +90% | +$1.94M | 0.01% | 1029 |
|
|
2015
Q3 | $2.13M | Buy |
66,344
+56,400
| +567% | +$1.91M | 0.01% | 1552 |
|
|
2015
Q2 | $303K | Sell |
9,944
-1,955
| -16% | -$40K | ﹤0.01% | 2683 |
|
|
2015
Q1 | $158K | Sell |
11,899
-190,771
| -94% | -$2.54M | ﹤0.01% | 2821 |
|
|
2014
Q4 | $2.93M | Buy |
202,670
+76,493
| +61% | +$1.3M | 0.01% | 1455 |
|
|
2014
Q3 | $2.66M | Buy |
126,177
+30,429
| +32% | +$687K | 0.01% | 1562 |
|
|
2014
Q2 | $2.85M | Sell |
95,748
-27,564
| -22% | -$871K | 0.01% | 1524 |
|
|
2014
Q1 | $2.96M | Sell |
123,312
-24,132
| -16% | -$615K | 0.01% | 1461 |
|
|
2013
Q4 | $3M | Buy |
147,444
+38,215
| +35% | +$1.14M | 0.01% | 1426 |
|
|
2013
Q3 | $5.16M | Sell |
109,229
-4,611
| -4% | -$178K | 0.02% | 1081 |
|
|
2013
Q2 | $4.33M | Buy |
+113,840
| New | +$4.07M | 0.02% | 1122 |
|
Other funds holding SRPT
EAM
Guggenheim Capital's SRPT Position: Q2 2026 in Review
Guggenheim Capital reduced its Sarepta Therapeutics (SRPT) stake by 13% in Q2 2026, selling an estimated $142K and leaving 51,046 shares worth $917K. The position accounts for 0.01% of the portfolio, ranked #1060.
Guggenheim Capital first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.85M in Q3 2018. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Guggenheim Capital held 51,046 shares of Sarepta Therapeutics worth $917K as of Q2 2026.
- Guggenheim Capital sold 7,483 Sarepta Therapeutics shares in Q2 2026, an estimated $142K.
- Sarepta Therapeutics made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1060 holding.
- Guggenheim Capital first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Guggenheim Capital's Sarepta Therapeutics position peaked at $6.85M in Q3 2018.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.